tetano
Editor, Senior Moderator
Antimicrob Agents Chemother. 2013 Dec 23. [Epub ahead of print]
Pharmacokinetics of orally administered oseltamivir in healthy obese and non-obese Thai subjects.
Jittamala P, Pukrittayakamee S, Tarning J, Lindegardh N, Hanpithakpong W, Taylor WR, Lawpoolsri S, Charunwattana P, Panapipat S, White NJ, Day NP.
Author information
Abstract
ObjectiveOseltamivir is the most widely used anti-influenza drug. In the H1N1 2009 pandemic, in which the influenza viruses were oseltamivir sensitive, obesity was identified as a risk factor for severe disease and unfavourable outcomes. The aim of this study was to investigate the pharmacokinetic properties of oseltamivir and its active metabolite, oseltamivir carboxylate, in obese and non-obese healthy subjects.MethodA single-dose randomized, two sequence cross-over study was conducted in 12 obese and 12 non-obese healthy Thai volunteers. Each volunteer was given 75 mg and 150 mg oseltamivir orally with an intervening wash-out period of more than 3 days. The pharmacokinetic properties of oseltamivir and oseltamivir carboxylate were evaluated using a non-compartmental approach.ResultsThe median (range) BMI for obese subjects was 33.8 kg/m2 (30.8-43.2) and 22.2 (18.8-24.2) for non-obese subjects. The pharmacokinetic parameters of oseltamivir carboxylate, the active metabolite of oseltamivir, were not significantly different between obese and non-obese subjects for both 75 mg and 150 mg doses.ConclusionsBoth doses were well tolerated. Despite the lower dose per kilogram body weight in obese subjects there was no significant difference in the exposure of oseltamivir carboxylate between the obese and non-obese group. Standard dosing is appropriate for obese subjects.
PMID:
24366750
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/24366750
Pharmacokinetics of orally administered oseltamivir in healthy obese and non-obese Thai subjects.
Jittamala P, Pukrittayakamee S, Tarning J, Lindegardh N, Hanpithakpong W, Taylor WR, Lawpoolsri S, Charunwattana P, Panapipat S, White NJ, Day NP.
Author information
Abstract
ObjectiveOseltamivir is the most widely used anti-influenza drug. In the H1N1 2009 pandemic, in which the influenza viruses were oseltamivir sensitive, obesity was identified as a risk factor for severe disease and unfavourable outcomes. The aim of this study was to investigate the pharmacokinetic properties of oseltamivir and its active metabolite, oseltamivir carboxylate, in obese and non-obese healthy subjects.MethodA single-dose randomized, two sequence cross-over study was conducted in 12 obese and 12 non-obese healthy Thai volunteers. Each volunteer was given 75 mg and 150 mg oseltamivir orally with an intervening wash-out period of more than 3 days. The pharmacokinetic properties of oseltamivir and oseltamivir carboxylate were evaluated using a non-compartmental approach.ResultsThe median (range) BMI for obese subjects was 33.8 kg/m2 (30.8-43.2) and 22.2 (18.8-24.2) for non-obese subjects. The pharmacokinetic parameters of oseltamivir carboxylate, the active metabolite of oseltamivir, were not significantly different between obese and non-obese subjects for both 75 mg and 150 mg doses.ConclusionsBoth doses were well tolerated. Despite the lower dose per kilogram body weight in obese subjects there was no significant difference in the exposure of oseltamivir carboxylate between the obese and non-obese group. Standard dosing is appropriate for obese subjects.
PMID:
24366750
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/24366750